Maze Therapeutics, Inc.
Ticker: 1842295
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY26 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|
| INCOME | |||
| Revenue | 20.00+700.0% | 2.50-98.5% | 165.00 |
| Total Income | 20.00+700.0% | 2.50-98.5% | 165.00 |
| EXPENSES | |||
| Expenditure | 46.55+74.1% | 26.73+5.0% | 25.45 |
| Tax | — | -0.28-116.2% | 1.73 |
| PROFIT | |||
| PBT | — | -25.03-117.8% | 140.78 |
| Net Profit | -24.21+2.2% | -24.75-117.8% | 139.06 |
| KEY METRICS | |||
| OPM % | -100.00% | -100.00%-184.58pp | 84.58% |
| NPM % | -100.00% | -100.00%-184.27pp | 84.28% |
| EPS | -0.45+95.6% | -10.25-273.1% | 5.92 |
Corporate Events
Board MeetingMAZE
202613Aug
Board Meeting
Maze Therapeutics, Inc. appointed Paula A. Johnson, M.D., M.…
SEC Filing ↗ Board MeetingMAZE
20268Jun
Board Meeting
Annual Meeting of Stockholders to elect Class I directors an…
SEC Filing ↗ Board MeetingMAZE
20261Jun
Board Meeting
Senior Vice President, Finance Resignation — Amy Bachrodt to…
SEC Filing ↗